Search

Displaying results 2561 - 2570 of 2960 in total
  1. Drug

    Nifurtimox

    go.drugbank.com/drugs/DB11820
    ApprovedInvestigational

    On August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials.

  2. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]

  3. Drug

    Clofedanol

    go.drugbank.com/drugs/DB04837
    ApprovedWithdrawn

    Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.

    Mixtures: Chlo Tuss EX
  4. Drug

    Inolimomab

    go.drugbank.com/drugs/DB15628
    Investigational

    It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.[A241385]

  5. Drug

    Hyaluronic acid

    go.drugbank.com/drugs/DB08818
    ApprovedInvestigationalVet approved

    [A230133] Several preparations of hyaluronic acid have been approved by the FDA and are available in oral, topical, and injectable forms.

    Products: E- Repair
  6. Drug

    Plasma protein fraction (human)

    go.drugbank.com/drugs/DB13968
    ApprovedInvestigational

    [A32512] It is already reviewed under the category of biologics by the FDA where the processing, required tests, requirements and labeling are incorporated.

  7. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065]

  8. Drug

    Retifanlimab

    go.drugbank.com/drugs/DB15766
    ApprovedInvestigational

    [L45608,L45618] On March 2023, the FDA granted accelerated approval to retifanlimab for a different indication, the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).

  9. Drug

    Gadopiclenol

    go.drugbank.com/drugs/DB17084
    ApprovedInvestigational

    [A254002,A254017] In September 2022, the use of gadopiclenol was approved by the FDA.

  10. Drug

    Olopatadine

    go.drugbank.com/drugs/DB00768
    Approved

    An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively.